In a recent study published in Cancer Discovery, Haldar and colleagues report the first-in-human evaluation of a pooled mutant (Kirsten rat sarcoma viral oncogene homolog) KRAS peptide vaccine in individuals at high risk of pancreatic ductal adenocarcinoma (PDAC). Vaccination induced broad and durable mutant KRAS-specific T-cell responses in most participants, providing a proof of concept for targeting oncogenic driver mutations before invasive pancreatic cancer develops.1
Twenty participants with hereditary predisposition to PDAC and a radiographic pancreatic abnormality received mKRAS-VAX, a pooled mutant KRAS peptide vaccine, at weeks 1, 3, 5 and 13. Eighteen of 20 participants met the prespecified immune-response criterion, with a median 18.2-fold increase in pooled mutant KRAS-specific T-cell responses. All treatment-related adverse events were grade 1–2, and longitudinal analyses in a subset showed that vaccine-induced KRAS-reactive T-cell clonotypes could persist for up to 2 years.1
The importance of the study lies not simply in demonstrating that a peptide vaccine can induce T-cell responses, but in when vaccination is attempted. PDAC develops over many years from precursor lesions, and mutant KRAS is already present in many pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) lesions. Vaccination at this stage may target premalignant cells before extensive tumor heterogeneity and the profoundly immunosuppressive microenvironment of established PDAC have developed.
The pooled approach may also be relevant because precursor lesions can contain different KRAS-mutant clones. Unlike prophylactic vaccines against oncogenic viruses, mKRAS-VAX aims to generate T cells against cells that have already acquired a somatic cancer-driving mutation.
The optimal disease setting has long been a challenge for cancer vaccines. As monotherapy, vaccination may be most attractive when tumor burden is minimal, whereas metastatic disease is likely to require combination strategies. Recent melanoma studies illustrate this spectrum.
In untreated advanced melanoma, combining pembrolizumab with an immune-modulatory peptide vaccine targeting IDO and PD-L1 numerically prolonged progression-free survival, although the prespecified significance threshold was not reached.2 Among anti-PD-1-naïve patients, median progression-free survival was 24.8 versus 11.0 months (HR 0.74, 95% CI 0.56–0.98). In resected high-risk melanoma, individualized neoantigen vaccination combined with pembrolizumab produced durable improvements in recurrence-free and distant metastasis-free survival.3 Importantly, the benefit was also pronounced among patients who were ctDNA-negative after surgery, supporting the concept that vaccination may be particularly effective in the setting of very low residual tumor burden. The benefit remained durable at 5 years, and the phase III INTerpath-001 trial has subsequently been announced to have met both its recurrence-free and distant metastasis-free survival endpoints.
Haldar and colleagues move the concept one stage earlier, to interception before invasive cancer has developed.
In PDAC, however, timing may only be one part of the equation. G12D generated the lowest median fold increase in T-cell response, 8.3-fold, compared with 43.9-fold for G12A, 33.7-fold for G12V and 21.8-fold for G12R.1 This is notable because G12D is also the most prevalent KRAS mutation in PDAC. In a contemporary clinicogenomic series, G12D accounted for 41% of KRAS-mutant PDAC, compared with 32% for G12V and 16% for G12R.4 This apparent paradox raises a question extending beyond vaccine design.
Could the high prevalence of G12D and its relatively poor immune recognition be biologically related? Figure 1 illustrates how allele-specific KRAS immune visibility may influence immune selection, pancreatic tumor evolution and cancer interception.Fig. 1Conceptual model linking allele-specific KRAS immune visibility to immune selection, pancreatic cancer interception and tumor evolution. a KRAS mutations arise early during pancreatic carcinogenesis and are already present in precursor lesions such as pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN). b Individual mutant KRAS variants may differ in immune visibility.
Haldar and colleagues observed marked differences in vaccine-induced immunogenicity, with G12D showing the weakest T-cell response despite being the most prevalent KRAS allele in pancreatic ductal adenocarcinoma (PDAC). c We propose that such allele-specific differences in immune recognition may also influence natural immunosurveillance and immunoediting. Better-recognized mutant clones may experience stronger immune-mediated negative selection, whereas poorly recognized clones such as G12D may more readily persist and expand. d Reduced G12D immune visibility could therefore contribute both to its evolutionary enrichment in PDAC and to reduced responsiveness to KRAS-directed vaccination. Conversely, vaccination may enhance mutant KRAS-specific T-cell recognition and provide an opportunity for cancer interception before invasive disease develops.
Created with BioRender.com
This interpretation is supported by unpublished observations from our group. We have detected pre-existing T-cell reactivity against common mutant KRAS variants in both patients with PDAC and healthy donors, with particularly limited recognition of G12D. Notably, several patients with G12D-mutant PDAC mounted substantial responses against other mutant KRAS peptides while showing markedly weaker recognition of G12D itself.
These observations argue against globally impaired T-cell responsiveness as the sole explanation and suggest that relatively weak G12D recognition may extend beyond vaccine-induced immunity.
These observations raise the possibility that allele-specific differences in immune visibility exist independently of vaccination and may have consequences much earlier during pancreatic tumor evolution. Population-scale genomic analyses demonstrate that HLA genotype can shape immune selection of oncogenic driver mutations.5 Preferential loss of the restricting HLA allele has been observed for G12V but not G12D in the context of HLA-A*11:01, consistent with differential immune pressure across KRAS variants.5 A well-recognized mutant allele may experience greater immune-mediated negative selection during tumorigenesis, whereas a poorly visible allele may more readily escape immunosurveillance. Reduced G12D recognition could therefore contribute both to lower vaccine responsiveness and to the evolutionary success of G12D-mutant pancreatic cells.
This remains a hypothesis, and immune selection is unlikely to be the sole determinant of KRAS allele distribution. Oncogenic fitness, tissue context, environmental exposures, and mutational processes may also contribute to the patterns observed during pancreatic tumor evolution. The Haldar study included only 20 individuals with a median follow-up of 16.5 months.
Whether vaccine-induced T cells can prevent PDAC will also depend on their persistence and access to premalignant lesions, effective antigen presentation by mutant cells and the local immune microenvironment. Although no participant developed PDAC during follow-up, the study was not designed or powered to establish cancer-preventive efficacy, and the absence of a control group and the limited follow-up preclude conclusions about whether vaccination altered the natural history of PDAC development.
An important next step is therefore to determine whether vaccine-induced KRAS-specific T cells traffic into pancreatic precursor lesions and recognize or eliminate mutant cells. Haldar and colleagues have initiated a window-of-opportunity cohort in patients undergoing resection of high-risk pancreatic lesions, allowing systemic vaccine-induced immunity to be related directly to biological effects in precancerous pancreatic tissue.1 This could provide an important bridge between circulating T-cell responses and the much more difficult demonstration that vaccination prevents invasive PDAC.
Overall, the significance of the Haldar study may extend beyond demonstrating the feasibility of KRAS-directed cancer interception. The relationship between KRAS allele prevalence and immune visibility raises the possibility that allele-specific immune recognition may influence not only vaccine responsiveness but also which KRAS-mutant clones escape immunosurveillance during pancreatic carcinogenesis. Understanding this relationship may be important both for developing preventive vaccines and for understanding the evolutionary biology of KRAS-mutant PDAC.